ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $281 | -34.7% | 14,013 | -8.2% | 0.00% | -33.3% |
| Q2 2023 | $430 | +77.7% | 15,258 | +8.5% | 0.00% | +50.0% |
| Q1 2023 | $242 | -12.3% | 14,065 | +2.5% | 0.00% | 0.0% |
| Q4 2022 | $276 | -99.9% | 13,717 | -7.9% | 0.00% | 0.0% |
| Q3 2022 | $323,000 | +53.8% | 14,894 | +99.7% | 0.00% | +100.0% |
| Q2 2022 | $210,000 | -2.3% | 7,460 | +59.8% | 0.00% | 0.0% |
| Q1 2022 | $215,000 | -40.8% | 4,669 | +8.0% | 0.00% | -50.0% |
| Q4 2021 | $363,000 | +67.3% | 4,323 | +32.5% | 0.00% | +100.0% |
| Q3 2021 | $217,000 | – | 3,262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |